Effects of cannabidiol in the treatment of patients with Parkinson’s disease: an exploratory double-blind trial.

Subject: Parkinson's Disease - PUBLISHED VIA Journal of Psychopharmacology

Author(s):
Chagas MH, Zuardi AW, Tumas V, Pena-Pereira MA, Sobreira ET, Bergamaschi MM, dos Santos AC, Teixeira AL, Hallak JE, Crippa JA

Department of Neuroscience and Behavior, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil INCT Translational Medicine (CNPq), São Paulo, Brazil Barretos School of Health Sciences - Dr. Paulo Prata, Barretos, Brazil mchagas@fmrp.usp.br mchagas@facisb.edu.br.

 View Source >> (Price: $40)

Related Studies:

Prospects for cannabinoid therapies in basal ganglia disorders.

Published via British Journal of Pharmacology

Cannabidiol for the treatment of psychosis in Parkinson’s disease.

Published via Journal of Psychopharmacology

Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson’s disease.

Published via Neurobiology of Disease

Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson’s disease: importance of antioxidant and cannabinoid receptor-independent properties.

Published via Brain Research

Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson’s disease patients: a case series.

Published via Journal of Clinical Pharmacy and Therapeutics

View all medical studies

Learn More About Cannabis

Website & branding by the Ganjapreneur in-house agency:

Blue Dream - Uplifted cannabis industry branding & marketing.

Uplifted cannabis industry branding & marketing.